Aflibercept in pediatric solid tumors: moving beyond the trap.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22869868.
- Also identified by DOI 10.1158/1078-0432.CCR-12-2212 and PMC identifier 3445740.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Angiogenesis plays a pivotal role in the growth and metastasis of adult and pediatric solid tumors. Clinical investigation of angiogenesis inhibitors is currently under way for childhood cancers. While the pediatric study of aflibercept provides a proof-of-principle, challenges remain in developing clinical endpoints and biomarkers of angiogenesis for pediatric trials.
Medical subject headings
- Antineoplastic Agents
- Neoplasms
- Receptors, Vascular Endothelial Growth Factor
- Recombinant Fusion Proteins